Home  Contact Us
  Follow Us On:
Advertising Advertising Free Newsletter Free E-Newsletter

Fosun unit, BioNTech to form joint venture to make Covid-19 vaccine
Published on: 2021-05-10
Share to
User Rating: / 0

A unit of Shanghai Fosun Pharmaceutical Group Co. agreed to establish a joint venture with BioNTech SE for the local production and commercialization of its Covid-19 vaccine.

Shanghai Fosun Pharmaceutical Industry Development will invest as much as $100 million in the partnership including cash, according to a statement to Shanghai Stock Exchange. BioNTech will invest up to $100 million through assets including production technology and a proprietary license.

Under the deal, Fosun Pharmaceutical Industrial will provide a manufacturing facility that has the potential to produce as much as 1 billion doses of the vaccine a year.



5月9日晚间,上海复星医药(集团)股份有限公司发布公告称,其控股子公司复星医药产业拟与德国拜恩泰科(BioNTech)投资设立合资公司,以实现 mRNA 新冠疫苗产品的本地化生产及商业化。根据双方签订的《许可协议》,复星医药产业应提供年产能可达10亿剂 mRNA新冠疫苗的生产设施,并将该设施作为出资的一部分注入合资公司。

Comments (0)Add Comment

Write comment

security code
Write the displayed characters

    Subscription    |     Advertising    |     Contact Us    |
Address: Magnetic Plaza, Building A4, 6th Floor, Binshui Xi Dao.
Nankai District. 300381 TIANJIN. PR CHINA
Tel: +86 22 23917700
E-mail: webmaster@businesstianjin.com
Copyright 2021 BusinessTianjin.com. All rights reserved.